Although BTIG still believes Liquidia has favorable odds of prevailing against United’s ‘327 patent, the firm reduced the probability of success for Liquidia’s drug, Yutrepia, in treating pulmonary ...

Shares of United Therapeutics (UTHR) and Liquidia (LQDA) are moving sharply in opposite directions in Friday afternoon trading. Shares of United ...

In a report released yesterday, Andreas Argyrides from Oppenheimer maintained a Sell rating on Liquidia Technologies, with a price target of $6.00. The company’s shares closed yesterday at $19.26.

We sifted through the Finviz stock screener to compile a list of the top 10 biotech stocks with an upside potential of over ...

Arquitos Capital Management gained 13.1% in Q2 2025. Learn how they turned market uncertainty into opportunity with Liquidia ...

It might be of some concern to shareholders to see the Liquidia Corporation (NASDAQ:LQDA) share price down 25% in the last month. In contrast, the return over three years has been impressive. In ...

Liquidia shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82.

Liquidia Corporation (NASDAQ:LQDA) is one of the best low priced pharma stocks to buy now. On June 24, Liquidia announced the receipt of an additional $50 million from Healthcare Royalty/HCRx. The ...

Liquidia Corporation (NASDAQ:LQDA) is one of the best low priced pharma stocks to buy now. On June 24, Liquidia announced the receipt of an additional $50 million from Healthcare Royalty/HCRx. The ...

Liquidia Corp (NASDAQ: LQDA), a $1.24 billion market cap biotech company, saw its Chief Human Resource Officer Sarah Krepp sell 2,673 shares of common stock on July 14, 2025, at a price of $14.28 ...

Bank of America Securities analyst Jason Gerberry maintained a Hold rating on Exelixis today. The company’s shares closed yesterday at $44.39. Take advantage of TipRanks Premium at 50% off! Unlock ...

United Therapeutics achieves 12th consecutive quarter of growth, fueled by Tyvaso success. Discover insights on upcoming catalysts & $1B share buyback.